Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Consumer & Luxury

Macy’s Faces Critical Test with Upcoming Q2 Earnings Report

Felix Baarz by Felix Baarz
August 31, 2025
in Consumer & Luxury, Earnings, Turnaround
0
Macy's Stock
0
SHARES
224
VIEWS
Share on FacebookShare on Twitter

All eyes are on Macy’s as the struggling retail giant prepares to release its second-quarter financial results next week. The report arrives amid lowered expectations and dimmed forecasts, presenting a crucial moment for the company’s ongoing turnaround efforts.

The company is scheduled to announce its quarterly performance before markets open on Wednesday, September 3rd. Market experts anticipate revenue to fall within a range of $4.69 to $4.74 billion, with projected earnings of $0.19 per share. Macy’s continues to navigate a complex landscape marked by trade tariffs, cautious consumer spending, and intense retail sector competition.

In a move that signaled persistent headwinds, Macy’s management had already tempered its full-year 2025 guidance. The company revised its annual profit forecast downward to a range of $1.60 to $2.00 per share. However, its revenue outlook for the year remained steady, maintained at $21.0 to $21.4 billion.

Should investors sell immediately? Or is it worth buying Macy's?

Turnaround Strategy Under Scrutiny

The core of the company’s future hinges on its ambitious “Bold New Chapter” restructuring plan. This radical strategy involves closing 150 underperforming locations by 2026 while simultaneously modernizing and expanding 125 of its most promising stores. Early indicators from the first quarter showed some positive momentum: credit card revenue surged by an impressive 31.6% to $154 million, and the gross margin held firm at 39.2%.

Despite these glimmers of progress, market sentiment remains largely skeptical. The average analyst price target for Macy’s stock sits around $13.22, only marginally above its current trading level. Sentiment among researchers is cautious; out of twelve analysts covering the stock, nine currently advise holding, while just one recommends buying.

For income-focused investors, the recent dividend payment of $0.1824 per share provides a modest silver lining. The central question, however, is whether this can offset the deeper structural issues the retailer faces. The upcoming quarterly figures will be pivotal in determining if Macy’s can finally initiate the long-awaited recovery or if it will confirm the market’s most pessimistic fears.

Ad

Macy's Stock: Buy or Sell?! New Macy's Analysis from February 8 delivers the answer:

The latest Macy's figures speak for themselves: Urgent action needed for Macy's investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Macy's: Buy or sell? Read more here...

Tags: Macy's
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

RBB Stock
Analysis

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026
DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Next Post
Costco Stock

Costco's Bold Membership Strategy: Rewarding Premium Customers

Marin Software Stock

Marin Software's Nasdaq Exit Culminates in Chapter 11 Restructuring and Shareholder Wipeout

Lufax Holding Stock

Leadership Shifts and Dividend Impact at Lufax Amid Trading Halt

Recommended

Kraft Heinz Stock

Is Kraft Heinz’s High Dividend Yield a Value Trap?

2 months ago
Middleby Stock

Middleby Shares Extend Decline Amid Mixed Signals and Lowered Guidance

6 months ago
Confluent Stock

Confluent Strengthens Leadership Team with New CTO Appointment

5 months ago

Vevye The Revolutionary Solution for Dry Eye Disease

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Trending

RBB Stock
Analysis

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

by SiterGedge
February 8, 2026
0

RBB Bancorp concluded its 2025 fiscal year with a notably stronger balance sheet, driven by a substantial...

Cassava Sciences Stock

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

February 8, 2026
DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review
  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com